Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura
Corresponding Author
George A. Stouffer MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Division of Cardiology, CB# 7075, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599Search for more papers by this authorJana Hirmerova MD
Department of Medicine, University Hospital Pilsen, Pilsen, Czech Republic
Search for more papers by this authorStephan Moll MD
Center for Thrombosis and Hemostasis, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorBryon Rubery MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorMark Napoli MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorE. Magnus Ohman MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Center for Thrombosis and Hemostasis, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorRoss Simpson MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorCorresponding Author
George A. Stouffer MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Division of Cardiology, CB# 7075, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599Search for more papers by this authorJana Hirmerova MD
Department of Medicine, University Hospital Pilsen, Pilsen, Czech Republic
Search for more papers by this authorStephan Moll MD
Center for Thrombosis and Hemostasis, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorBryon Rubery MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorMark Napoli MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorE. Magnus Ohman MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Center for Thrombosis and Hemostasis, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorRoss Simpson MD
C.V. Richardson Cardiac Catheterization Laboratory, Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorAbstract
The appropriate regimen of platelet inhibitors that should be used in patients with immune thrombocytopenia purpura (ITP; formerly called idiopathic thrombocytopenic purpura) who are undergoing percutaneous coronary intervention is unclear. We report the case of a patient with ITP who underwent two separate coronary interventions. The first involved the use of aspirin and a cutting balloon to treat obstructive disease of the left circumflex. When the patient presented with restenosis, he received eptifibatide, clopidogrel, and an intracoronary stent. He is currently 16 months removed from his second procedure and remains physically active without any anginal symptoms. Percutaneous revascularization in patients with ITP remains a challenge and this therapeutic approach, while ultimately successful in the patient, requires further validation. Catheter Cardiovasc Interv 2004;61:364–367. © 2004 Wiley-Liss, Inc.
REFERENCES
- 1 Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995–1008.
- 2 Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714–1719.
- 3 Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227–231.
- 4 Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study investigators. N Engl J Med 1998; 339: 1665–1671.
- 5 Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–1089.
- 6 Izumi M, Tsuchikane E, Funamoto M, Kobayashi T, Sumitsuji S, Otsuji S, Sakurai M, Awata N. Final results of the CAPAS trial. Am Heart J 2001; 142: 782–789.
- 7 Kondo T, Kawaguchi K, Awaji Y, Mochizuki M. Immediate and chronic results of cutting balloon angioplasty: a matched comparison with conventional angioplasty. Clin Cardiol 1997; 20: 459–463.
- 8 Antman EM. Decision making with cardiac troponin tests. N Engl J Med 2002; 346: 2079–2082.
- 9 Crouch ED, Watson LE. Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura: a case report and literature review. Angiology 2002; 53: 113–117.
- 10 Gottlieb S. Intravenous immunoglobulin increases risk of thrombotic events. Br Med J 2002; 324: 1056.
- 11 Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000; 75: 83–85.
- 12 Koch CA, Archer TP, Kraut EH. Myocardial ischemia in a patient with chronic refractory idiopathic thrombocytopenic purpura. Arch Intern Med 1997; 157: 2668–2622.
- 13 Paolini R, Fabris F, Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). Am J Hematol 2000; 65: 177–178.
- 14 Stouffer GA, Humphries JE, Gibson RS, Williams ME. The role of platelets in unstable angina: conversion of chronic stable angina to rest angina concurrent with a rapid increase in the platelet count. J Vasc Med Biol 1993; 4: 9–12.
- 15 Caputo RP, Abraham S, Churchill D. Transradial coronary stent placement in a patient with severe idiopathic autoimmune thrombocytopenic purpura. J Invas Cardiol 2000; 12: 365–368.
- 16 Fuchi T, Kondo T, Sase K, Takahashi M. Primary percutaneous transluminal coronary angioplasty performed for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. Jpn Circ J 1999; 63: 133–136.
- 17 Kikuchi S, Hayashi Y, Fujioka S, Kukita H, Ochi N. A case of intracoronary stent implanted for acute myocardial infarction in an elderly patient with idiopathic thrombocytopenic purpura. Jpn J Geriatr 2002; 39: 88–93.
